Management of the website has been transferred from NHMRC to the Commonwealth Department of Health. Disruption to site users as a consequence of this change should be minimal.

Clinical Trial Details

Metabolic Effects of SERMs (Selective Oestrogen Receptor Modulators) in healthy men and healthy postmenopausal women

Print record Print record
Trial Information

Broad Health Condition Metabolic and Endocrine

Specific Health ConditionNormal metabolism and endocrine development and function

Trial FocusEducational / counselling / training

Recruitment statusRecruiting


Anticipated date of first participant enrolment27/11/2006

Anticipated date of last participant enrolment27/11/2006

Phase of TrialNot Applicable

Has the study received ethics approval?Further information iconApproved

Trial summary

We aim to investigate and compare the effects of raloxifene and tamoxifen (two most commonly used SERMs) in healthy men and women on the growth hormone system and metabolism.

Key inclusion criteria

Healthy postmenopausal women and healthy men the same age

Minimum age50 Years

Maximum age80 Years

GenderBoth males and females

Can Healthy volunteers participate?Yes

Key exclusion criteria

obesity, diabetes, cancer, kidney or liver diseases, deep vein thrombosis
Contact details and further information

Sponsor Primary Sponsor Type: Hospital
Primary Sponsor Name: Department of Endocrinology, St Vincent's Hospital
Primary Sponsor Address: 390 Victoria St Darlinghurst, NSW 2010
Primary Sponsor Country: Australia

Trial IDACTRN12607000586415

Contact person for information and recruitment
Prof Ken Ho, MD, FRACP, Head of Dept of Endocrinology, St Vincent’s Hospital
Pituitary Research Unit Garvan Institute of Medical Research 384 Victoria Street Darlinghurst 2010 NSW
02 9295 8482
02 9295 8481
Further information